Rating Change
Mizuho reiterated its Outperform rating on Enliven Therapeutics, Inc. (NASDAQ:ELVN) on August 18, 2026.
reiterateNASDAQ:ELVN
Mizuho Reiterates Outperform Rating on Enliven Therapeutics, Inc. (ELVN)
Mizuho reiterated its Outperform rating on Enliven Therapeutics, Inc. (NASDAQ:ELVN) on August 18, 2026.
At publication ·
What changed
Enliven Therapeutics, Inc. (NASDAQ:ELVN) · reiterate
- Firm
- Mizuho
- Rating
- Outperform to Outperform
- Price at event
- $60.07
- Market capitalization
- $1.1B
At a glance
Key takeaways
- Mizuho reiterated an Outperform rating on Enliven Therapeutics (ELVN) on August 18, 2026, with the stock trading at $60.07 and a market capitalization of $1.1 billion.
Market Context
Enliven Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $60.07 with a market capitalization of $1.1B.
Analyst coverage from Mizuho provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Enliven Therapeutics, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Enliven Therapeutics, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 18, 2026 | William Blair | Outperform | N/A |
| Aug 18, 2026 | Barclays | Overweight | N/A |
| Aug 18, 2026 | Mizuho | Outperform | N/A |
| Aug 06, 2026 | Goldman Sachs | Buy | N/A |
| Aug 06, 2026 | Guggenheim | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View ELVN Stock Page
Frequently Asked Questions
What does the Outperform rating mean for ELVN?
A rating of Outperform from Mizuho reflects the analyst's outlook on Enliven Therapeutics, Inc. (NASDAQ:ELVN). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the ELVN forecast page.
